中药对脑缺血再灌注损伤临床前模型的抗炎作用:神经保护药物发现与治疗前景
本文综述中药(含活性化合物、药材、复方及汤剂)在脑缺血再灌注损伤(IRI)临床前模型中的抗炎与神经保护作用。动物模型以大脑中动脉闭塞(MCAO)或创伤性脑损伤(TBI)为主,丹参酮为代表性先导化合物。炎症反应参与原发与继发性缺血病理,抗炎策略靶向炎性细胞因子、活性氧、一氧化氮及转录因子。
要点
- 中药在脑IRI动物模型中显示神经保护与抗炎作用,丹参酮为代表性先导化合物。
- 炎症反应参与脑IRI原发与继发性病理,抗炎是潜在神经保护策略。
- 中药临床疗效需盲法、安慰剂对照随机试验及严谨meta分析验证。
核心结论
- 中药及其来源活性化合物在脑IRI临床前模型中具有抗炎与神经保护潜力,但进入临床前需进一步验证。
研究设计与样本
- 综述类文章,未报告系统检索范围与样本量。
主要发现
- 中药在脑IRI动物模型中显示显著治疗效果,丹参酮在MCAO或TBI动物模型中 confer 神经保护。
- 炎症反应参与脑IRI原发与继发性缺血病理,抗炎策略靶向促炎与抗炎细胞因子、其他炎性介质、活性氧、一氧化氮及多种转录因子。
关键数值与推荐
- 原文未报告具体数值、比例、阈值、剂量、样本量或P值。
临床怎么用
- 中药临床用于脑IRI疾病显示神经功能缺损改善趋势,但需盲法、安慰剂对照随机试验与meta分析评估。
- 从复杂中药复方中分离鉴定具有神经保护作用的单体化合物,可作为新药先导化合物开发。
局限性
- 原文未系统报告检索范围与纳入研究质量评价。
- 中药临床疗效证据需更严谨的随机对照试验与meta分析支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired brain ischemia-and reperfusion-injury (IRI), including both Ischemic stroke (IS) and Traumatic Brain injury (TBI), is one of the most common causes of disability and death in adults and represents a major burden in both western and developing countries worldwide. China's clinical neurological therapeutic experience in the use of traditional Chinese medicines (TCMs), including TCM-derived active compounds, Chinese herbs, TCM formulations and decoction, in brain IRI diseases indicated a trend of significant improvement in patients' neurological deficits, calling for blind, placebo-controlled and randomized clinical trials with careful meta-analysis evaluation. There are many TCMs in use for brain IRI therapy in China with significant therapeutic effects in preclinical studies using different brain IRI-animal. The basic hypothesis in this field claims that in order to avoid the toxicity and side effects of the complex TCM formulas, individual isolated and identified compounds that exhibited neuroprotective properties could be used as lead compounds for the development of novel drugs. China's efforts in promoting TCMs have contributed to an explosive growth of the preclinical research dedicated to the isolation and identification of TCM-derived neuroprotective lead compounds. Tanshinone, is a typical example of TCM-derived lead compounds conferring neuroprotection toward IRI in animals with brain middle cerebral artery occlusion (MCAO) or TBI models. Recent reports show the significance of the inflammatory response accompanying brain IRI. This response appears to contribute to both primary and secondary ischemic pathology, and therefore anti-inflammatory strategies have become popular by targeting pro-inflammatory and anti-inflammatory cytokines, other inflammatory mediators, reactive oxygen species, nitric oxide, and several transcriptional factors. Here, we review recent selected studies and discuss further considerations for critical reevaluation of the neuroprotection hypothesis of TCMs in IRI therapy. Moreover, we will emphasize several TCM's mechanisms of action and attempt to address the most promising compounds and the obstacles to be overcome before they will enter the clinic for IRI therapy. We hope that this review will further help in investigations of neuroprotective effects of novel molecular entities isolated from Chinese herbal medicines and will stimulate performance of clinical trials of Chinese herbal medicine-derived drugs in IRI patients.
引用
- Peng T, Jiang Y, Farhan M, et al. Anti-inflammatory Effects of Traditional Chinese Medicines on Preclinical in vivo Models of Brain Ischemia-Reperfusion-Injury: Prospects for Neuroprotective Drug Discovery and Therapy. Front Pharmacol. 2019. PMID: 30930774. doi:10.3389/fphar.2019.00204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。